https://www.selleckchem.com/products/anlotinib-al3818.html PURPOSE The study aims to assess the visual outcomes of pseudophakic cystoid macular oedema (CMO) as compared to age- and co-pathology matched controls, the costs of treatment and follow up, as well as the patient reported outcomes using the novel Cat-PROM5 questionnaire. SETTING West Suffolk NHS Foundation Trust, UK DESIGN Matched Case-Control Study METHODS 52 eyes of 49 patients developed CMO over an 18-month period. Age and co-pathology matched patients were identified from clinical records over the same time period in a 21 ratio (90 eyes). Post-operative clinical outcomes were recorded including treatments received, costs of treatments and patient recorded outcome measures using the Cat-PROM5 RESULTS Patients with CMO reported a significantly worse outcome from surgery than controls. Furthermore, CMO patients had significantly worse visual acuity after surgery than controls (CMO logMAR 0.40 ±0.33, n=37; controls 0.30 ±0.33; p less then 0.05) despite there being no difference in pre-operative visual acuity. In patients with epiretinal membrane (ERM), notably those with CMO had worse patient reported outcomes than controls with ERM, and only 18% received prophylactic corticosteroid injection at surgery compared with 63.6% of controls. CMO resulted in an excess of 266 outpatient appointments, with 388 weeks of topical therapy, 18 orbital floor injections, and 6 intravitreal steroid injections, 5 intravitreal anti-VEGF injections and one intravitreal dexamethasone implant with an excess expenditure of £216.81 per case. CONCLUSIONS Patients developing CMO following cataract surgery suffer with reduced visual acuity at 4 - 6 weeks, patient-reported visual outcomes, increased number of hospital appointments, treatments and costs.Robot-assisted gait training (RAGT) has been introduced in clinical practice to increase training intensity in patients with neurological disorders. In this observational study, we inve